Patience with development-stage food additive developer Senomyx (SNMX)
has really started paying off over the last six months. Investors
started bidding up the shares on expectations of FDA approval of key
product S617, as well as optimism that the company's direct sales effort
will lead to greater adoption of products already shown to replace
significant amounts of sugar or other sweeteners and those that enhance
savory flavors.
Up almost 170% from where I recommended
the stock as a Top Idea, it's tempting to call it a day and take the
winnings off the table. While obtaining the GRAS designation removes a
critical commercialization hurdle for Senomyx's partners PepsiCo (PEP) and Firmenich,
there are still many operating risks remaining, including commercial
introduction and acceptance of products using Senomyx's additives. I'm
bullish about the prospects of S617 in beverages like sodas and sports
drinks, but I'm not so bullish yet on the opportunities in foods like
baked goods. If adoption there proves stronger than I currently expect,
the upside for the shares could be considerable.
Read more here:
With GRAS Status In Hand, It's Close To 'Go Time' For Senomyx's Partners
No comments:
Post a Comment